Described herein are compounds and pharmaceutical compositions containing such compounds which are prodrugs of ALOX-15 inhibitors. Also described herein are methods for using such compounds in the treatment of disease.

Disclosed are compounds of Formula 1, including all geometric and stereoisomers, N-oxides, and salts thereof, ##STR00001##
wherein W is O or S; V is a direct bond or NR.sup.3; Q is or CR.sup.6aR.sup.6b, O, NR.sup.7, C═N—O—R.sup.7 or C(═O); Y is —C(R.sup.5)═N—O—(CR.sup.8aR.sup.8b).sub.p—X—(CR.sup.9aR.sup.9b).sub.q—SiR.sup.10aR.sup.10bR.sup.10c; or a phenyl ring substituted as defined in the disclosure; or Z; and R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5, R.sup.6a, R.sup.6b, R.sup.7, R.sup.8a, R.sup.8b, R.sup.9a, R.sup.9b, R.sup.10a, R.sup.10b, R.sup.10c, Z, p and q are as defined in the disclosure. Also disclosed are compositions containing the compounds of Formula 1 and methods for controlling plant disease caused by a fungal pathogen comprising applying an effective amount of a compound or a composition of the invention.

Disclosed are compounds of Formula 1, including all geometric and stereoisomers, N-oxides, and salts thereof, ##STR00001##
wherein W is O or S; V is a direct bond or NR.sup.3; Q is or CR.sup.6aR.sup.6b, O, NR.sup.7, C═N—O—R.sup.7 or C(═O); Y is —C(R.sup.5)═N—O—(CR.sup.8aR.sup.8b).sub.p—X—(CR.sup.9aR.sup.9b).sub.q—SiR.sup.10aR.sup.10bR.sup.10c; or a phenyl ring substituted as defined in the disclosure; or Z; and R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5, R.sup.6a, R.sup.6b, R.sup.7, R.sup.8a, R.sup.8b, R.sup.9a, R.sup.9b, R.sup.10a, R.sup.10b, R.sup.10c, Z, p and q are as defined in the disclosure. Also disclosed are compositions containing the compounds of Formula 1 and methods for controlling plant disease caused by a fungal pathogen comprising applying an effective amount of a compound or a composition of the invention.

A crystal form of 2-(3,5-dimethyl-1H-pyrazol-1-yl)-5-methylphenol which is stable and has high purity for preservation, industrial manufacturing, and circulation, and process for providing the same by using a boron compound.

A crystal form of 2-(3,5-dimethyl-1H-pyrazol-1-yl)-5-methylphenol which is stable and has high purity for preservation, industrial manufacturing, and circulation, and process for providing the same by using a boron compound.

Compositions that modulate the activity of signal transducer and activator of transcription-3 (STAT3) activity as well as their methods of use, such as treatment and imaging are provided. Compositions contain small molecules such as substituted pyrazoles and are useful in treatment of diseases related to the activity of STAT3 including, for example, cancer and other diseases.

Described herein are compounds of Formula (I), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Compounds described herein are useful for inhibiting arginine methyltransferase activity. Methods of using the compounds for treating arginine methyltransferase-mediated disorders are also described. ##STR00001##

Described herein are compounds of Formula (I), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Compounds described herein are useful for inhibiting arginine methyltransferase activity. Methods of using the compounds for treating arginine methyltransferase-mediated disorders are also described. ##STR00001##

The present invention disclosed a process for the synthesis of anthranilic diamide compound of formula (I),

##STR00001## wherein, R.sup.1, R.sup.2, R.sup.3a, R.sup.3b, R.sup.3c, R.sup.4, R.sup.5, R.sup.6 and Z are as defined in the detailed description. The process comprising the step of obtaining a mono- or dicyano substituted aniline compound of formula (IV) which is then converted to an anthranilic acid compound of formula (V) or an anthranilic amide compound of formula (Va). Further, the compound of formula (VI) can be optionally synthesized from compound of formula (IV or V or Va).

##STR00002##

The present invention disclosed a process for the synthesis of anthranilic diamide compound of formula (I),

##STR00001## wherein, R.sup.1, R.sup.2, R.sup.3a, R.sup.3b, R.sup.3c, R.sup.4, R.sup.5, R.sup.6 and Z are as defined in the detailed description. The process comprising the step of obtaining a mono- or dicyano substituted aniline compound of formula (IV) which is then converted to an anthranilic acid compound of formula (V) or an anthranilic amide compound of formula (Va). Further, the compound of formula (VI) can be optionally synthesized from compound of formula (IV or V or Va).

##STR00002##